0000899243-23-007331.txt : 20230307 0000899243-23-007331.hdr.sgml : 20230307 20230307160519 ACCESSION NUMBER: 0000899243-23-007331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230303 FILED AS OF DATE: 20230307 DATE AS OF CHANGE: 20230307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reinhart Harald CENTRAL INDEX KEY: 0001835824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 23712549 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR STREET 2: PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-03 0 0001704292 Zai Lab Ltd ZLAB 0001835824 Reinhart Harald C/O ZAI LAB LIMITED 314 MAIN STREET, 4TH FLOOR, SUITE 100 CAMBRIDGE MA 02142 0 1 0 0 See Remarks American Depositary Shares 2023-03-03 4 M 0 11480 3.00 A 30438 D American Depositary Shares 2023-03-03 4 S 0 11480 40.00 D 18958 D Stock Options (Right to Buy) 3.00 2023-03-03 4 M 0 11480 0.00 D 2027-05-12 American Depositary Shares 11480 0 D Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. The reported transaction was effected pursuant to a sale plan adopted by the Reporting Person, dated 08/23/2022, that expires on 06/30/2023 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The options vest in equal installments over four years beginning on 5/12/2018, the first anniversary of the date of grant. President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases /s/ Bruce Blefeld, Attorney-in-Fact 2023-03-07